PLEASANTON, CALIF., NANJING, CHINA, May 21, 2021 - IASO Biotherapeutics announces today that its clinical trial application for the in-house developed CD19-CD22 fully human dual-targeted CAR T-cell th...
PLEASANTON, CALIF., NANJING, CHINA, May 21, 2021 - IASO Biotherapeutics announces today that its clinical trial application for the in-house developed CD19-CD22 fully human dual-targeted CAR T-cell th...
PLEASANTON, CALIF., NANJING, CHINA, May 19, 2021 - IASO Biotherapeutics (IASO Bio) today announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has ...
PLEASANTON, CALIF., NANJING, CHINA, February 22, 2021-- IASO Biotherapeutics (IASO Bio) and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the Center for Drug Evaluatio...
2020 Nanjing International Life & Health Conference was successfully held in Nanjing International Expo Center during December 9 to 11. The conference was guided by Nanjing Municipal Government an...
IASO Bio, a clinical-stage company focused on developing and commercializing novel cellular immunotherapy to treat cancer, is pleasant to announce the appointment of Dr. Biao Zheng as Chief Scientific...
IASO Biotherapeutics recently announced the completion of $60 million in series B financing led by GL Ventures, which is a venture capital fund of Hillhouse Capital focusing on early-stage innovative ...
Nanjing, China., Nov 23, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will gi...
September 10th,2019, IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, announced today that the Company has received ...
Nanjing, China., Sept 1, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will gi...